Openbookopenbook
Equity
CytoMed Therapeutics Limited Ordinary Shares(GDTC)
USD --+0.00%
Reward35Moderate
Risk51Moderate
📊75%Data
Revenue growing 101% YoY
GDTC
+0.0 · +0.00%
USD · NASDAQ
CytoMed Therapeutics Limited Ordinary Shares | Healthcare
Structurally Challenged
Market Cap:22.53M
ℹ️
Reward Rating
35
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
51
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on GDTC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: S$5.00.

What is CytoMed Therapeutics Limited Ordinary Shares?

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

GDTC · Verdict

Limited reward · elevated risk

GDTC stands out on balance sheet and volatility, but watch the cash flow signal.

Based on 88% data coverage

GDTC · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet76/100

    Current ratio 9.89

  • Volatility75/100

    Above average

Watchouts 4

  • Cash flow6/100

    -5787% free-cash-flow margin

  • Growth25/100

    Rev -14.8% CAGR · earnings +7.1%

  • Profitability32/100

    -3621% net margin · -42% ROE

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is CytoMed Therapeutics Limited Ordinary Shares?

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 22.53M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (35)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap22.53M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.68
52 Week Low0.7282
Last AnnualDecember
IPO Date4/14/2023
IncorporatedUSA
Shares Outstanding12M
No. of Employees43
IndustryBiotechnology
ExchangeNASDAQ
Beta-0.349
CurrencyUSD · Reports in SGD
Websitew2.cytomed.sg
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.